中國(guó)生物官方微信公號(hào)消息

China Biological Official WeChat Public Account News

經(jīng)國(guó)務(wù)院聯(lián)防聯(lián)控機(jī)制有關(guān)部門(mén)組織論證,國(guó)藥集團(tuán)中國(guó)生物北京生物制品研究所的新冠病毒滅活疫苗獲批在3-17歲人群中緊急使用

According to the demonstration organized by the relevant departments of the Joint Prevention and Control Mechanism of the State Council, the new coronavirus inactivated vaccine of the Beijing Institute of Biological Products of Sinopharm Group has been approved for emergency use in people aged 3-17

國(guó)藥集團(tuán)中國(guó)生物新冠疫苗3-17歲年齡組已經(jīng)在河南完成I/II期臨床試驗(yàn)，3-17歲人群免后中和抗體陽(yáng)轉(zhuǎn)率為100%，中和抗體GMT和陽(yáng)轉(zhuǎn)率與成人組相比無(wú)顯著性差異，接種后安全性良好，不良反應(yīng)主要為發(fā)熱和接種部位疼痛，嚴(yán)重程度以1級(jí)為主，未見(jiàn)嚴(yán)重不良反應(yīng)，不良反應(yīng)發(fā)生率隨接種劑次增加而逐漸降低

Sinopharm China Bio-New Crown Vaccine 3-17 years old age group has completed phase I/II clinical trials in Henan. After 3-17 years of age, the neutralizing antibody positive conversion rate is 100%, and the neutralizing antibody GMT and positive conversion rate is the same as that of adults There is no significant difference between the two groups. The safety after vaccination is good. The adverse reactions are mainly fever and pain at the inoculation site. The severity is mainly grade 1, and no serious adverse reactions are seen. The incidence of adverse reactions gradually decreases with the increase in the number of inoculations.

 

From website: https://my-h5news.app.xinhuanet.com/